DOJ Says Marijuana Rescheduling Opponents Have 'Pocketbook Interests'

DOJ Challenges Standing of Rescheduling Opponents

The Justice Department's filing argues that objectors lack legitimate scientific grounds and are instead protecting financial stakes in maintaining prohibition. In a brief submitted to the Drug Enforcement Administration's administrative law judge overseeing the rescheduling hearing, DOJ attorneys characterized the opposition coalition—which includes law enforcement groups, addiction treatment providers, and anti-legalization advocacy organizations—as financially motivated actors seeking to preserve revenue streams tied to cannabis criminalization.

The filing doesn't name specific objectors but references parties who have formally intervened in the DEA rescheduling proceeding initiated in May 2024. Those parties include Smart Approaches to Marijuana (SAM), the National Sheriffs' Association, and several state attorneys general from prohibition states. DOJ's characterization marks the sharpest public pushback against rescheduling opponents since the Biden administration formally recommended the Schedule III move in August 2023.

Here's the cleanest read on DOJ's strategy: by questioning opponents' motives, the government is laying groundwork to limit their evidentiary role in the administrative hearing. If the ALJ agrees that objectors' concerns are economic rather than scientific, their testimony and expert witnesses could be excluded or given reduced weight in the final rescheduling determination.

Financial Stakes in Cannabis Prohibition

Law enforcement agencies, private prison operators, and drug-testing companies generate billions annually from marijuana enforcement and interdiction. The DOJ filing implicitly references these revenue streams without naming specific industries. According to the most recent FBI Uniform Crime Report data, marijuana arrests still account for roughly 350,000 annual bookings nationwide despite state-level legalization in 24 states. Each arrest generates fees, fines, and court costs that fund local law enforcement budgets.

Private prison corporations including CoreCivic and GEO Group hold federal contracts worth $3.2 billion annually for detention services, a portion of which involves drug offenders. Rescheduling to Schedule III wouldn't legalize marijuana federally but would remove it from the most restrictive category, potentially reducing federal prosecutions and incarceration for cannabis-related offenses. That shift threatens a revenue model built on prohibition.

Drug-testing laboratories represent another financial interest. The workplace drug-screening industry generates an estimated $4.5 billion per year, with marijuana tests comprising the majority of panels. Rescheduling wouldn't eliminate employer testing rights. But it could accelerate state-level employment protections for off-duty cannabis use, shrinking the addressable market for testing firms.

The objectors' economic exposure is real and quantifiable, which is precisely why DOJ is raising the conflict-of-interest argument now rather than waiting for the evidentiary phase.

What Happens Next in the Rescheduling Timeline

The DEA's administrative law judge is expected to rule on standing and evidentiary motions by September 2026, with a final rescheduling decision projected for late 2026 or early 2027. The ALJ hearing, which began in May 2026, is the formal adversarial process required under the Administrative Procedure Act before the DEA can finalize any schedule change. Objectors have the right to present evidence and cross-examine government witnesses, but only if the judge grants them full party status.

If the ALJ limits objectors' participation based on DOJ's pocketbook-interest argument, the hearing timeline could compress significantly. Fewer witnesses mean narrower evidentiary scope. That would accelerate the record-building phase. Conversely, if objectors retain full standing, the proceeding could extend into 2027 as each party presents expert testimony on marijuana's abuse potential, medical utility, and scheduling criteria under the Controlled Substances Act.

Once the ALJ issues a recommended decision, the DEA Administrator has final authority to adopt, modify, or reject the recommendation. That decision is then subject to judicial review in federal court. For context on the full procedural arc and political variables at play, see the CannIntel topic hub on DEA rescheduling.

Watch for the ALJ's ruling on DOJ's motion to limit objector standing, expected by mid-September. That decision will determine whether this proceeding runs six months or eighteen.